Baotang Zhao - Viaderma Chief Sales Officer
| VDRM Stock | USD 0.01 0.0004 4.44% |
Executive
Mr. Zhao Baotang is Chief Sales Officer of Decor Products International Inc., since July 23, 2009 since 2009.
| Age | 45 |
| Tenure | 15 years |
| Phone | 310 496 5744 |
| Web | https://viadermalicensing.com |
Viaderma Management Efficiency
The company has return on total asset (ROA) of (0.9123) % which means that it has lost $0.9123 on every $100 spent on assets. This is way below average. Viaderma's management efficiency ratios could be used to measure how well Viaderma manages its routine affairs as well as how well it operates its assets and liabilities. ViaDerma, Inc. operates as a specialty pharmaceutical company in the United States. ViaDerma, Inc. was incorporated in 2007 and is headquartered in Marina Del Rey, California. Viaderma operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on OTC Exchange. Viaderma [VDRM] is a Pink Sheet which is traded between independent brokers as part of over-the-counter (OTC) trading.Management Performance
| Return On Asset | -0.91 |
Viaderma Leadership Team
Elected by the shareholders, the Viaderma's board of directors comprises two types of representatives: Viaderma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Viaderma. The board's role is to monitor Viaderma's management team and ensure that shareholders' interests are well served. Viaderma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Viaderma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Shaowen Zhang, Manager of Production | ||
| Christopher Otiko, Chief Founder | ||
| Zhang Xie, Corporate Secretary and Director | ||
| Baotang Zhao, Chief Sales Officer | ||
| Qing Lin, CFO and Director | ||
| MPH MD, Medical Board |
Viaderma Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Viaderma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Asset | -0.91 | |||
| Operating Margin | (13.28) % | |||
| Current Valuation | 6.18 M | |||
| Shares Outstanding | 137.32 K | |||
| Price To Earning | 0.03 X | |||
| Price To Book | 0 X | |||
| Price To Sales | 2.01 X | |||
| Revenue | 44.69 K | |||
| Gross Profit | 37.63 K | |||
| EBITDA | (592.43 K) |
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectOther Information on Investing in Viaderma Pink Sheet
Viaderma financial ratios help investors to determine whether Viaderma Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Viaderma with respect to the benefits of owning Viaderma security.